Abstracts tagged "longitudinal studies"

Abstract Number: 2752 • 2013 ACR/ARHP Annual Meeting
Good, Moderate and Poor Outcome Trajectories Of Pain Severity In Early Symptomatic Knee Osteoarthritis; 5 Year Follow-Up Of Check study
Janet Wesseling¹, Alex N. Bastick², Sita M.A. Bierma-Zeinstra³ and Johannes W.J. Bijlsma⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²General Practice, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ³Orthopaedics and General Practice, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Knee pain is often the first sign of knee OA (osteoarthritis) and it is known that its course can be very different between patients over…
Abstract Number: 2328 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Susan P. Wood⁴, Ketti K. Terry⁴, Hiroyuki Nakamura⁵, Yukako Ohno⁵, David Gruben⁴, Birgitta Benda⁶, Lisy Wang⁴ and Richard Riese⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Japan Inc, Tokyo, Japan, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
Abstract Number: 1942 • 2013 ACR/ARHP Annual Meeting
Ultrasound Shows Tenosynovitis to be Frequently Present as Well As Sensitive to Change in RA Patients On Biologic Medication
Hilde B. Hammer, Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Ultrasound (US) (grey scale (GS) and power Doppler (PD)) is a sensitive tool for examination of tenosynovitis in patients with rheumatoid arthritis (RA). The…
Abstract Number: 1430 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Subcutaneous Tocilizumab Monotherapy In a Long-Term Extension Study In Japanese Rheumatoid Arthritis Patients
Atsushi Ogata, Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan
Background/Purpose: Tocilizumab (TCZ) blocks interleukin-6-receptor signaling and is an effective rheumatoid arthritis (RA) therapy. The MUSASHI1 and SUMMACTA2 studies showed the efficacy and safety of…
Abstract Number: 1303 • 2013 ACR/ARHP Annual Meeting
Variations In Disease Activity and Therapeutic Management Of Rheumatoid Arthritis In Different International Regions: A Comparison Of Data From The Corrona International and Corrona United States Registries
Dimitrios A. Pappas¹, Kathy Lampl², Joel M. Kremer³, Sebastião C. Radominski⁴, Janos Gal⁵, Fredrik Nyberg⁶, Anand N. Malaviya⁷, Aimée Whitworth⁸, Oscar Luis Rillo⁹, Allan Gibofsky¹⁰, Tatiana Popkova¹¹, Meilien Ho¹², Ieda Laurindo¹³, George W. Reed⁸, Eduardo Mario Kerzberg¹⁴, Laura Horne¹⁵, Roman Záhora¹⁶, Katherine C. Saunders¹⁷, Bernado Pons-Estel¹⁸, Alina U. Onofrei¹⁹ and Jeffrey D. Greenberg²⁰, ¹Columbia University, New York, NY, ²AstraZeneca R&D Wilmington, Wilmington, DE, ³Center for Rheumatology, Albany Medical College, Albany, NY, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Rheumatology, County Hospital, Kecskemet, Hungary, ⁶AstraZeneca R&D, Mölndal, Sweden, ⁷Rheumatology, Consultant Rheumatologist, ISIC Superspeciality Hospital, New Delhi-11007-, India, ⁸CORRONA, Inc., Southborough, MA, ⁹Hospital Tornú, Capital Federal, Argentina, ¹⁰Medicine and Public Health, Hospital for Special Surgery, New York, NY, ¹¹Research Institute of Rheumatology -Russian Academy of Medical Science, Moscow, Russia, ¹²AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹³Rheumatology, Universidade de São Paulo, São Paulo, Brazil, ¹⁴Rheumatology, J. M. Ramos Mejía Hospital, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, ¹⁵AstraZeneca, Wilmington, DE, ¹⁶Revmatologická ambulance, Terezin, Czech Republic, ¹⁷Corrona, LLC., Southborough, MA, ¹⁸Hospital Provincial de Rosario, Rosario, Argentina, ¹⁹University of Massachusetts Medical School, Worcester, MA, ²⁰Rheumatology, NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: The CORRONA International (C.Intl) rheumatoid arthritis (RA) registry is the first multinational RA registry uniformly collecting baseline and longitudinal data. We explored variations in…
Abstract Number: 1271 • 2013 ACR/ARHP Annual Meeting
Longitudinal Disease Trajectory Of Juvenile Dermatomyositis
Lily Siok Hoon Lim^1,2, Eleanor Pullenayegum³, Dafna D. Gladman⁴, Earl D. Silverman⁵ and Brian M. Feldman⁶, ¹Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada, ³Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: 1) To determine the longitudinal disease activity trajectory of an inception cohort of Juvenile Dermatomyositis (JDM) patients, 2) To identify predictor(s) for longitudinal disease…
Abstract Number: 1232 • 2013 ACR/ARHP Annual Meeting
Osteoporosis In Rheumatoid Arthritis – Still a Threat In The Biologic Era?
Glenn Haugeberg¹, Torhild Garen², Hege Sommerseth³, Anne Prøven³ and Knut Helgetveit³, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Rheumatology, Martina Hansens Hospital, Bærum, Norway
Background/Purpose: Osteoporosis is a well-known extra articular manifestation in rheumatoid arthritis (RA). In RA biologic disease modifying anti rheumatic drugs (DMARDs) has been shown to…
Abstract Number: 1110 • 2012 ACR/ARHP Annual Meeting
Radiologic Progression in Hand Osteoarthritis (OA) Over 2.6 Years – Data From the Sekoia Trial
Emmanuel Maheu¹, Christian Cadet² and Francis Berenbaum¹, ¹Rheumatology, AP-HP, St Antoine Hospital, Paris, France, ²Rheumatology, Paris, France
Background/Purpose: Hand OA is a frequent polyarticular disease. Few is known with respect to its radiological progression over time, which in addition is difficult to…
Abstract Number: 1032 • 2012 ACR/ARHP Annual Meeting
Medial Meniscal Root Tears and the Association with Meniscal Extrusion, Prevalent Cartilage Damage and Longitudinal Cartilage Loss: The MOST Study
Mohamed Jarraya¹, David T. Felson², Daichi Hayashi¹, Frank Roemer³, Yuqing Zhang⁴, Jingbo Niu⁵, Michel Crema⁶, Martin Englund⁷, John A. Lynch⁸, Michael C. Nevitt⁹, James Torner¹⁰, C.E. Lewis¹¹ and Ali Guermazi⁶, ¹Department of Radiology, Boston University, Boston, MA, ²Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ³Radiology, Klinikum Augsburg, Augsburg, Germany, ⁴Clinical Epidemiology Unit, Boston University, Boston, MA, ⁵Boston University, Boston, MA, ⁶Radiology, Boston University, Boston, MA, ⁷Department of Orthopedics, Lund University, Lund, Sweden, ⁸Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA, ⁹Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ¹⁰Epidemiology, University of Iowa, Iowa City, IA, ¹¹University of Alabama at Birmingham, Birmingham City, AL
Background/Purpose: The meniscal root is a ligamentous structure that anchors the posterior horn of the meniscus to the tibial plateau. The association of isolated meniscal…
Abstract Number: 816 • 2012 ACR/ARHP Annual Meeting
Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout
Eswar Krishnan, Medicine, Standford University, Palo Alto, CA
Background/Purpose: The kidney is the major organ of urate excretion in humans. Yet, there are few studies that assess whether reduced glomerular filtration and/or kidney…
Abstract Number: 653 • 2012 ACR/ARHP Annual Meeting
Longitudinal Analysis of Plasma Factors and Disease Activity Identifies Von Willebrand Factor As A Biomarker of Lupus Flare
Mikhail Olferiev¹, Kyriakos A. Kirou¹, Elena Gkrouzman¹, Dorthe Lundsgaard², Klaus S. Frederiksen³, Jan Fleckner⁴ and Mary K. Crow⁵, ¹Hospital for Special Surgery, New York, NY, ²Inflammation Science, Biopharmaceuticals Research Unit, Novo Nordisk A/S, Måløv, Denmark, ³Novo Nordisk A/S, Søborg, Denmark, ⁴NovoNordisk, Copenhagen, Denmark, ⁵Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Lupus, a chronic autoimmune disease, is characterized by a variable clinical course, with periods of active disease termed flares. The severity of flares can…
Abstract Number: 2514 • 2012 ACR/ARHP Annual Meeting
Racial/Ethnic Trends in Incidence and Prevalence of Rheumatoid Arthritis in a Large Multi-Ethnic Managed Care Population
Aniket A. Kawatkar¹, Cecilia Portugal¹, Li-Hao Chu² and Rajan Iyer³, ¹Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ²Department of Research and Evaluation,, Kaiser Permanente Southern California, Pasadena, ³Department of Research and Evaluation,, Kaiser Permanente Southern California, Pasadena, CA
Background/Purpose: As epidemiologic studies throughout the world have shown significant variations, we sought to characterize racial differences in longitudinal epidemiologic trends of adult rheumatoid arthritis…
Abstract Number: 448 • 2012 ACR/ARHP Annual Meeting
Sustained and Cumulated Response Over Time in Rheumatoid Arthritis Patients Treated with Rituximab After Initial Failure of Anti Tumor Necrosis Factor Agents
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca⁵, ¹Internal Medicine, Cantacuzino Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Clinic Hospital "Sf. Maria", Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, ⁵Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania
Background/Purpose: Although anti-TNF therapies moved forward the treatment of rheumatoid arthritis (RA), failure of the first anti-TNF medication is not uncommon. Many times modifying dosage/frequency…
Abstract Number: 2490 • 2012 ACR/ARHP Annual Meeting
Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
K. L. Winthrop¹, H. Valdez², E. Mortensen³, R. Chew⁴, S. Krishnaswami⁵, T. Kawabata⁵ and R. Riese⁴, ¹Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ²Pfizer Inc., New York, NY, ³Global Medical Affairs, Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Patients (pts) with RA are at increased risk for herpes zoster (HZ) i.e. ‘shingles'. Tofacitinib, a novel oral Janus kinase inhibitor investigated as a…
Abstract Number: 449 • 2012 ACR/ARHP Annual Meeting
Rituximab After First Anti Tumor Necrosis Factor Failure Is More Efficient with High Impact in Reducing Time and Costs to Achieve Superior Rates of Low Disease Activity and Remission
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca¹, ¹Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania
Background/Purpose: Significant steps were done in creating new medications for treatment of rheumatoid arthritis (RA). As RA seriously affects the patients’ quality of life, the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].